Danaher Reports Fourth Quarter and Full Year 2025 Results
DHRWASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise...
Danaher to Present at J.P. Morgan Healthcare Conference
DHRWASHINGTON, Jan. 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026 at 11:15 a.m. PT. The...
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
DHR(NYSE:DHR) NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the...
DANAHER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Danaher Corporation - DHR
DHR(NYSE:DHR) NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporation (NYSE: DHR). On April 25, 2023, the Company disclosed that "[r]evenues decreased 7.0% year-over-year to $7.2 billion, with a 4.0% non-GAAP core revenue decrease, due to the impact of lower COVID-19 revenue, and 6.0% non-GAAP base business core revenue
EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
DHRNEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We e
Danaher Schedules Second Quarter 2025 Earnings Conference Call
DHRWASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company...
Here's How Much $1000 Invested In Danaher 10 Years Ago Would Be Worth Today
DHRHow Do Investors Really Feel About Danaher?
DHRSCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech
DHR$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
DHRMarket Whales and Their Recent Bets on DHR Options
DHRP/E Ratio Insights for Danaher
DHRAldevron And Integrated DNA Technologies Manufacture World's First mRNA-Based Personalized CRISPR Gene Editing Drug Product To Treat Infant With Urea Cycle Disorder
DHR$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
DHRKytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers
DHRMarket Whales and Their Recent Bets on DHR Options
DHR$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
DHRHow Is The Market Feeling About Danaher?
DHRAnalyst Sees Opportunity In Danaher Stock As Sentiment Improves
DHRDanaher beat Q1 forecasts with $5.74 billion in sales and $1.88 EPS. Analyst sees upside ahead as bioprocess growth and CDMO demand improve.
RBC Capital Reiterates Outperform on Danaher, Maintains $250 Price Target
DHRGoldman Sachs Maintains Buy on Danaher, Lowers Price Target to $240
DHRGuggenheim Reiterates Buy on Danaher, Maintains $250 Price Target
DHRUBS Maintains Buy on Danaher, Lowers Price Target to $240
DHRWhat 12 Analyst Ratings Have To Say About Danaher
DHRBaird Maintains Outperform on Danaher, Lowers Price Target to $225
DHRDanaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst
DHRDanaher beat Q1 2025 estimates and analysts noted resilience despite macro pressures and China-related headwinds.
JP Morgan Maintains Overweight on Danaher, Lowers Price Target to $260
DHRJefferies Maintains Buy on Danaher, Lowers Price Target to $230
DHRDanaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'
DHRDanaher posted Q1 revenue of $5.74 billion and EPS of $1.88, both above estimates, with bioprocessing and diagnostics driving better-than-expected results.
For FY2025, Danaher Initiates Adjusted EPS Guidance Of $7.60 To $7.75 Vs. Consensus Of $7.68, Reaffirms That Non-GAAP Core Revenue Will Grow Approximately 3% Year-Over-Year
DHRFor Q2 2025, Danaher Anticipates That Non-GAAP Core Revenue Will Grow Low-Single Digits Year-Over-Year
DHRDanaher Q1 2025 Adj EPS $1.88 Beats $1.64 Estimate, Sales $5.74B Beat $5.59B Estimate
DHREarnings Outlook For Danaher
DHR$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
DHRSmart Money Is Betting Big In DHR Options
DHRThis Western Digital Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
DHRBarclays Upgrades Danaher to Overweight, Lowers Price Target to $205
DHRDanaher Unusual Options Activity For April 02
DHRLooking Into Danaher's Recent Short Interest
DHRBehind the Scenes of Danaher's Latest Options Trends
DHRCheck Out What Whales Are Doing With DHR
DHRUnpacking the Latest Options Trading Trends in Danaher
DHRForecasting The Future: 10 Analyst Projections For Danaher
DHRStifel Upgrades Danaher to Buy, Announces $260 Price Target
DHRDanaher 's Beckman Coulter Announces FDA Clearance Of Its DxC 500i Clinical Analyzer
DHRIf You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
DHRDanaher's Options Frenzy: What You Need to Know
DHRDanaher Increases Quarterly Dividend From $0.27 To $0.32
DHRP/E Ratio Insights for Danaher
DHRDanaher's Options Frenzy: What You Need to Know
DHR